Bluebird bio is a commercial-stage gene therapy company with three FDA-approved, one-time treatments for rare genetic diseases, all sold exclusively in the U.S. The core technology works by collecting a patient's own stem cells, genetically modifying them outside the body using bluebird's lentiviral vector platform to add a functional copy of a defective gene, then infusing the cells back into the patient. By using the patient's own cells, the therapies avoid the serious risks of traditional donor-based stem cell transplants. Bluebird's three products are LYFGENIA for sickle cell disease (priced at $3.1M), ZYNTEGLO for transfusion-dependent β-thalassemia ($2.8M), and SKYSONA for early cerebral adrenoleukodystrophy ($3.0M). Treatments are administered through a network of over 70 qualified treatment centers. Revenue is recognized at patient infusion, roughly two quarters after cell collection begins. At current volumes, bluebird operates at negative gross margins due to high fixed manufacturing costs, but targets 70%+ gross margins as volumes scale. To address reimbursement hurdles at these price points, bluebird has structured outcomes-based agreements with payers covering roughly 200M U.S. lives, under which bluebird reimburses payers up to 80% of therapy cost if patients fail to hit defined clinical outcomes. Growth is focused on scaling LYFGENIA in sickle cell disease, expanding Medicaid access, deepening utilization across its QTC network, and doubling manufacturing capacity in 2026. In February 2025, bluebird announced a definitive merger agreement to be acquired for $3.00 per share plus a contingent value right.